Chlamydia vaccine - SIGA

Drug Profile

Chlamydia vaccine - SIGA

Latest Information Update: 22 Sep 2014

Price : $50

At a glance

  • Originator Oregon State University
  • Developer Oregon State University; SIGA Technologies
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chlamydial infections

Most Recent Events

  • 27 Apr 2005 Discontinued - Preclinical for Chlamydial infections in USA (unspecified route)
  • 26 Nov 2004 This vaccine is still in active development
  • 16 Aug 2002 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top